Ameriprise’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$380K Sell
339,714
-71,618
-17% -$80.2K ﹤0.01% 3588
2025
Q1
$325K Buy
411,332
+234,171
+132% +$185K ﹤0.01% 3620
2024
Q4
$292K Sell
177,161
-72,581
-29% -$120K ﹤0.01% 3706
2024
Q3
$874K Buy
249,742
+7,310
+3% +$25.6K ﹤0.01% 3263
2024
Q2
$795K Sell
242,432
-41,958
-15% -$138K ﹤0.01% 3247
2024
Q1
$2.09M Buy
284,390
+32,741
+13% +$240K ﹤0.01% 2850
2023
Q4
$941K Sell
251,649
-23,843
-9% -$89.2K ﹤0.01% 3210
2023
Q3
$584K Buy
275,492
+27,394
+11% +$58.1K ﹤0.01% 3350
2023
Q2
$1.18M Buy
248,098
+171,039
+222% +$814K ﹤0.01% 3100
2023
Q1
$439K Buy
77,059
+58,233
+309% +$332K ﹤0.01% 3472
2022
Q4
$190K Sell
18,826
-66,231
-78% -$668K ﹤0.01% 3716
2022
Q3
$1.91M Buy
85,057
+5,183
+6% +$116K ﹤0.01% 2807
2022
Q2
$1.98M Buy
79,874
+9,742
+14% +$241K ﹤0.01% 2811
2022
Q1
$2.72M Sell
70,132
-441,520
-86% -$17.1M ﹤0.01% 2780
2021
Q4
$29.9M Sell
511,652
-285,019
-36% -$16.7M 0.01% 1120
2021
Q3
$47.2M Buy
796,671
+128,223
+19% +$7.6M 0.02% 792
2021
Q2
$58M Buy
668,448
+46,743
+8% +$4.06M 0.02% 732
2021
Q1
$51.3M Buy
621,705
+357,066
+135% +$29.4M 0.02% 760
2020
Q4
$24.1M Sell
264,639
-74,186
-22% -$6.75M 0.01% 1102
2020
Q3
$13.5M Sell
338,825
-15,233
-4% -$609K 0.01% 1339
2020
Q2
$12.1M Sell
354,058
-150,968
-30% -$5.18M 0.01% 1386
2020
Q1
$11.2M Sell
505,026
-1,445,247
-74% -$32.1M 0.01% 1310
2019
Q4
$38.2M Buy
1,950,273
+447,711
+30% +$8.76M 0.02% 819
2019
Q3
$23.3M Buy
1,502,562
+799,286
+114% +$12.4M 0.01% 1030
2019
Q2
$14.3M Buy
+703,276
New +$14.3M 0.01% 1438
2018
Q2
Sell
-88,364
Closed -$862K 3646
2018
Q1
$862K Buy
+88,364
New +$862K ﹤0.01% 3031